Table 2.
Observational studies of systemic drug therapies as first-line treatments for combined HCC
| Study design | n | Systemic chemotherapy (1st-line), n (%) | OS, months | PFS, months | Reference | ||
|---|---|---|---|---|---|---|---|
| Retrospective | 30 | GEM + L-OHP | 18 (60.0) | 16.2 | 3 (10.0) | 9.0 | [3] |
| GEM + L-OHP + bevacizumab | 9 (30.0) | ||||||
| GEM + CDDP | 3 (10.0) | ||||||
| Retrospective | 36 | GEM + CDDP | 12 (33.3) | 10.2 | 3.0 | [4] | |
| 5-FU + CDDP | 11 (30.5) | 11.9 | 3.8 | ||||
| Sorafenib | 5 (13.8) | 3.5 | 1.6 | ||||
| Other | 8 (22.2) | 8.1 | 2.8 | ||||
| Retrospective | 68 | GEM + CDDP/L-OHP | 41 (60.3) | 11.5 | 8.0 | [5] | |
| GEM±5-FU | 16 (23.5) | 11.7 | 6.6 | ||||
| Sorafenib | 7 (10.3) | 9.6 | 4.8 | ||||
| Other | 4 (5.9) | N/A | N/A | ||||
| Retrospective | 99 | Sorafenib | 62 (62.6) | 10.7 | 4.2 | [6] | |
| Cytotoxic drug | 37 (37.4) | 10.6 | 2.9 |
OS, overall survival; PFS, progression-free survival; GEM, gemcitabine; L-OHP, oxaliplatin; CDDP, cisplatin; 5-FU, fluorouracil; N/A, not available.